Novel therapies, often with expensive price tags and finite patient populations, require strategic new positioning if they are to have maximum positive impact. Here, Alpharmaxim’s William Hind ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached statistical ...

Takeda has bolstered its neuroscience pipeline by licensing drug candidates from California biotech AcuraStem targeting PIKfyve, which is gathering attention as a drug target in amyotrophic ...

There's been another twist to the tale of Advanz Pharma's efforts to keep its primary biliary cholangitis (PBC) therapy Ocaliva on the market in the EU. Earlier this week, the European Commission ...

Roche’s anti-TIGIT drug tiragolumab has failed a lung cancer study, denting enthusiasm for the programme just as there were signs that it was getting back on track after a series of ...

2023 was a tough year for biotechs with declines in private fundraising and public listings, but the UK industry stood up well under the pressure, according to new figures from the BioIndustry ...

The journey of medicinal cannabis has seen remarkable adoption worldwide. Once marginalised and stigmatised, cannabis is now making its way into the mainstream of medicine and healthcare, offering ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

It is well established that focusing on diversity in clinical trials is essential for developing therapies that are safe and effective for different patient populations. But are clinical research ...

An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial, leaving them sifting through the data for signals of efficacy.

To encourage the uptake of complex therapies in clinical practice, brand teams must ensure they use data-driven insights to understand the needs and preferences of healthcare professionals (HCPs ...

Heartseed Inc. and Novo Nordisk - in partnership since June 2021 - have announced that the first patient has been successfully dosed in a clinical study with HS-001, a cell therapy designed to ...